Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E23.97 EPS (ttm)5.76 Insider Own0.05% Shs Outstand2.70B Perf Week-1.31%
Market Cap372.89B Forward P/E17.56 EPS next Y7.86 Insider Trans-12.73% Shs Float2.69B Perf Month-3.14%
Income15.83B PEG3.41 EPS next Q1.72 Inst Own67.80% Short Float0.51% Perf Quarter2.40%
Sales74.36B P/S5.01 EPS this Y8.30% Inst Trans-0.03% Short Ratio2.58 Perf Half Y8.16%
Book/sh27.56 P/B5.00 EPS next Y7.91% ROA10.60% Target Price145.33 Perf Year19.56%
Cash/sh6.00 P/C22.97 EPS next 5Y7.03% ROE22.10% 52W Range109.32 - 144.35 Perf YTD19.72%
Dividend3.36 P/FCF38.78 EPS past 5Y11.20% ROI17.00% 52W High-4.45% Beta0.81
Dividend %2.44% Quick Ratio1.00 Sales past 5Y2.00% Gross Margin68.30% 52W Low26.17% ATR1.60
Employees126400 Current Ratio1.30 Sales Q/Q10.30% Oper. Margin26.10% RSI (14)45.32 Volatility0.76% 1.12%
OptionableYes Debt/Eq0.48 EPS Q/Q-10.40% Profit Margin21.30% Rel Volume0.81 Prev Close138.00
ShortableYes LT Debt/Eq0.36 EarningsOct 17 BMO Payout55.90% Avg Volume5.27M Price137.93
Recom2.50 SMA20-1.71% SMA500.92% SMA2006.04% Volume4,266,264 Change-0.05%
Oct-18-17Reiterated Stifel Hold $140 → $142
Oct-18-17Reiterated RBC Capital Mkts Outperform $144 → $147
Oct-18-17Reiterated Leerink Partners Outperform $150 → $165
Oct-16-17Reiterated Jefferies Buy $157 → $160
Oct-11-17Upgrade Jefferies Hold → Buy
Oct-09-17Upgrade Wells Fargo Market Perform → Outperform
Sep-25-17Initiated Citigroup Neutral $140
Sep-20-17Downgrade Goldman Neutral → Sell $125 → $130
Jul-21-17Downgrade BTIG Research Neutral → Sell $110
Jul-21-17Downgrade Alembic Global Advisors Neutral → Underweight
Jul-20-17Resumed Credit Suisse Outperform $148
Jul-05-17Reiterated Morgan Stanley Overweight $135 → $140
May-18-17Reiterated Stifel Hold $124 → $128
May-15-17Upgrade JP Morgan Neutral → Overweight
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
Nov-21-17 08:03AM  November Pharma And Biotech Dividend Stocks To Look Out For Simply Wall St.
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
07:31AM  Why JNJ Stock Is Still a Buy despite Weak 3Q17 Results Market Realist
Nov-20-17 05:26PM  Stay away from big pharma? CNBC Videos
12:55PM  A Look at Mercks Cardiovascular Portfolio in 3Q17 Market Realist
12:47PM  Johnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference PR Newswire
10:31AM  How the Pricing Outlook in International Medical Technology Impacts JNJ Today Market Realist
09:02AM  JNJ Exits Insulin Pump Business amid Stiff Competition Market Realist
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
07:32AM  How JNJ Plans to Address the Portfolio Gaps in its Spine Business? Market Realist
Nov-19-17 11:06AM  3 Blue-Chip Dividend Stocks You Can Keep Forever Motley Fool
08:00AM  3 Top Index Funds to Keep You in the Investing Game Motley Fool
Nov-18-17 10:39AM  Fears grow that popularity of ETFs is a ticking time bomb MarketWatch
Nov-17-17 04:10PM  This Drove Down JNJs Orthopedic Segment Performance in 3Q17 Market Realist
03:16PM  Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU Zacks
02:40PM  Gauging JNJs Recovery from the 3Q17 Hurricanes Market Realist
01:08PM  How JNJs Medical Devices Business Restructuring Efforts Are Panning Out Market Realist
11:27AM  Applied Materials Headed Higher in Long Term TheStreet.com
08:01AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Nov-16-17 04:10PM  J&J wins California lawsuit claiming asbestos in talc caused cancer Reuters
03:36PM  Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today Motley Fool
03:33PM  How J&J Can Be A $150 Stock Forbes
02:32PM  J&J wins Calif. lawsuit claiming asbestos in talc caused cancer Reuters
02:23PM  Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case PR Newswire
02:21PM  Johnson & Johnson hit with $247 million verdict in hip implant trial Reuters
02:12PM  Johnson & Johnson hit with $247 mln verdict in hip implant trial Reuters
01:55PM  Apple, Cisco Power Nasdaq To High; Own These 3 Buffett Stocks? Investor's Business Daily
12:58PM  Johnson & Johnson hit with $247 mln verdict in hip implant trial Reuters
12:33PM  J&J Ordered to Pay $247 Million Over Defective Hips Bloomberg
10:35AM  Achillion Pharmaceuticals Gears Up for Secondary Offering 24/7 Wall St.
09:06AM  AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio Zacks
07:13AM  Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo Zacks
Nov-15-17 08:17PM  3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock Motley Fool
01:56PM  Despite Valeant Improvement, VRX Stock Price Is Still Too High InvestorPlace
01:37PM  Why Achillion Pharmaceuticals Stock Is Falling Today Motley Fool
01:32PM  J&J Presents Positive New Data for Diabetes Drug Invokana Zacks
01:30PM  Achillion (ACHN) Shares Down as J&J Announces Stake Sale Zacks
12:28PM  Achillion Heel: Stock Plunges as J&J Exits Barrons.com
11:07AM  Is Johnson & Johnson (JNJ) A Financially Sound Company? Simply Wall St.
09:01AM  Behind Novartiss Respiratory Drug Performance in 3Q17 Market Realist
08:16AM  Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer Zacks
Nov-14-17 04:34PM  Achillion shares drop as J&J to sell large stake MarketWatch
04:16PM  Allergan's Vraylar Gets FDA Nod for Maintenance Therapy Zacks
03:55PM  How Novartiss Cosentyx Is Positioned after 3Q17 Market Realist
09:20AM  Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis Zacks
04:06AM  Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy Reuters
Nov-13-17 09:25AM  AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate Zacks
09:00AM  Can Marijuana Cure Alzheimer's Disease? Motley Fool
08:27AM  Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems PR Newswire
05:27AM  Bill Gates Is Now Tackling Alzheimers With a Huge Investment in Dementia Research Fortune
Nov-10-17 09:30AM  Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y Zacks
07:32AM  Zimmer Biomets Knee Sales in 3Q17: Whats Ahead? Market Realist
Nov-09-17 07:01PM  Cramer Remix: Why an AT&T-Time Warner combo would be worth buying CNBC
07:00PM  Cramer Remix: Why an AT&T-Time Warner combo would be wort... CNBC Videos
06:56PM  JNJ CEO: Need to work with Washington for 'smart tax poli... CNBC Videos
06:55PM  5 traits successful CEOs & military leaders share CNBC Videos
06:50PM  Johnson & Johnson CEO: Washington needs to work with us f... CNBC Videos
06:48PM  Cramer: Successful CEOs and military leaders have these 5... CNBC Videos
11:10AM  Pharma ETFs Down Post Q3 Earnings Zacks
09:01AM  Analysts Recommendations for Celgene in November 2017 Market Realist
09:00AM  AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View Zacks
Nov-08-17 02:59PM  Indexes Quiet, Small Caps Recover; 4 Hot Stocks Gap Up In Price Investor's Business Daily
02:15PM  How Celgenes Revlimid and Pomalyst Are Positioned after 3Q17 Market Realist
12:46PM  Top 3 Dividend Stocks in 2017 Investopedia
12:41PM  How Did Celgene Perform in 3Q17? Market Realist
10:28AM  Johnson & Johnson -- Moody's assigns Aaa to J&J's sr. notes; stable outlook Moody's
Nov-07-17 04:47PM  What Lies in Store for Pharma ETFs? Zacks
Nov-06-17 11:22AM  Boeing Co Stock Has Enough Oomph to Keep Rolling Higher InvestorPlace
10:41AM  3 Stock Dips Begging to Be Bought InvestorPlace
08:32AM  Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah Zacks
07:00AM  J&J's Stelara shows promise against lupus in study Reuters
03:58AM  Bayer in bid to broaden use of anti-clotting drug Xarelto Reuters
Nov-04-17 07:30PM  J&J's Stelara shows promise against lupus in study Reuters
01:07PM  A Dividend ETF For November And Beyond Benzinga
Nov-03-17 01:08PM  Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus Zacks
12:20PM  Kiplinger Dividend 15: Our Top Dividend Picks Kiplinger
07:30AM  Why the Healthcare Sector Struggled in October Market Realist
Nov-02-17 12:20PM  This Health Care ETF Wins With More Exposure to Smaller Firms Kiplinger
11:10AM  Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss Zacks
09:01AM  5 Things Pfizer's Management Just Said That You Don't Want to Miss Motley Fool
Nov-01-17 04:44PM  Ohio AG gives McKesson, others 30 days to be 'part of the solution' on addictive opioids American City Business Journals
03:12PM  FDA Approves AstraZeneca's Blood Cancer Drug TheStreet.com
02:42PM  Family of cancer victim want another review in talc case Associated Press
08:02AM  If I Could Buy Only 1 Stock, This Would Be It Motley Fool
Oct-31-17 12:27PM  Why Geron Corporation Stock Is Jumping Today Motley Fool
12:02PM  New Jersey Joins States Suing Purdue Pharma for Opioid Marketing Bloomberg
11:20AM  How AbbVies Drugs Performed in 3Q17 Market Realist
10:36AM  Pfizer Inc. Stock Is Boring, and Thats Perfect InvestorPlace
07:33AM  Why Intuitive Surgicals Da Vinci System Placements Looks Lumpy outside the US Market Realist
06:23AM  3 Stocks With Microsoft-like Return Potential Motley Fool
Oct-30-17 07:45PM  Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson Motley Fool
01:40PM  Behind Intuitive Surgicals Key Revenue Growth Drivers in 3Q17 Market Realist
12:31PM  Why TransEnterix Stock Is Rebounding Today Motley Fool
12:09PM  Investor Group Presses Drugmakers, Distributors Over Opioids Bloomberg
09:56AM  Investor group presses U.S. drug companies on opioid controls Reuters
09:33AM  The 3 Best Diabetes Stocks to Buy in 2018 Motley Fool
09:31AM  How to Invest in Healthcare Motley Fool
09:30AM  Pandemic alert: Tuberculosis is world's No. 1 infectious killer CNBC
08:09AM  Johnson & Johnson CEO: A lot of change going on in health care Fox Business Videos
08:07AM  Secretary of Veterans Affairs: You're seeing a VA that is reforming Fox Business Videos
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusExec VP, Chief Scientific OffOct 31Option Exercise0.0075,4920203,142Nov 02 05:01 PM
Stoffels PaulusExec VP, Chief Scientific OffJul 24Option Exercise72.54102,6927,449,278230,342Jul 26 11:49 AM
Stoffels PaulusExec VP, Chief Scientific OffJul 24Sale133.14102,69213,672,629127,650Jul 26 11:49 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Option Exercise61.7582,5915,099,994226,693Jul 24 11:06 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Sale136.7282,59111,291,478144,102Jul 24 11:06 AM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM